Unfortunately, rare 'orphan' diseases are under-funded because there aren't enough patients to make them profitable. That's not true. Genzyme (acquired by San

Unfortunately, rare 'orphan' diseases are under-funded because there aren't enough patients to make them profitable. That's not true. Genzyme (acquired by Sanofi for $20B) has a whole portfolio of orphan disease drugs, they do nothing else. The success of rare disease drugs actually inspired a lot of big pharma to get into it too.